Zealand, Lilly Partner on Diabetes Peptide Drugs
By Cormac Sheridan
Friday, August 30, 2013
Zealand Pharma A/S added Eli Lilly and Co. to its roster of big pharma diabetes partners, entering a research collaboration with the Indianapolis-based firm that could eventually lead to a novel, first-in-class therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.